Health officials in the United Kingdom have reported that a vaccine given during pregnancy to protect against Respiratory Syncytial Virus (RSV) is highly effective at preventing severe illness in infants. Real-world data from the UK Health Security Agency (UKHSA) shows the vaccine, Abrysvo by Pfizer, is more than 80% effective at preventing hospital admissions for RSV in babies under six months old.
RSV is a common respiratory virus that typically causes mild, cold-like symptoms but can lead to severe lower respiratory tract infections like bronchiolitis and pneumonia in infants. It is a leading cause of hospitalization in young children globally. The maternal vaccine works by boosting the mother's antibodies, which are then passed to the baby, providing protection in the vulnerable first months after birth.
The UK began offering the single-dose vaccine to pregnant women from September 2024, aiming to protect babies born during the winter RSV season. Early results from the first season of the program, covering approximately 150,000 babies, confirm the high level of protection observed in clinical trials. Similar maternal RSV vaccines and monoclonal antibody immunizations for infants are being rolled out in other countries, including the United States.
Public health experts highlight this as a significant step in reducing the substantial burden RSV places on healthcare systems and families each winter. The success of the program supports the continued use of maternal immunization as a key strategy to shield newborns from serious infectious diseases.
